The robust quality of the food, pharma, and environmental testing markets is evident from the growth in revenues by 33 percent in 2008 (Media center, 2008). Despite a strong position Eurofins faces certain challenges due to macro drivers like regulations, the global supply chain, and consumer awareness.
Eurofins is planning to close two European facilities and one US site as they want to consolidate and assign assets (GenomeWeb, 2007). It has recently acquired three genomics companies with facilities in Germany and the US and Japan. This has taken place to the competitive market scenario as there is overcapacity in the market and investments are not justified.
Until the mid-1990s, Europe’s biotech industry was closely modeled on the strategies and institutional support structures as in the United States. Any commercialization of biotech research took place directly between academics and the pharmaceutical company. Some firms go in for royalty-bearing licensing like Mycogen to Ciba while others have non-loyalty bearing licensing like AgrEvo and then some even enter into royalties and fees like Monsanto (Renkoski, 1997).
The German biotech industry has suddenly taken off whereas the UK biotech industry has become stagnant. According to Casper and Kettler (2001), there is no one right way to organize commercial biotechnology. Multinational Biotechnology Companies and their Lobby Group.
Please type your essay title, choose your document type, enter your email and we send you essay samples